How do you utilize p53 NGS testing in your treatment planning for patients with CLL?

When I approach consideration of treatment, it is clear that TP53 mutation or del(17)(p13) chromosome region on interphase cytogenetics identifies a group of patients at risk for progression after treatment with a venetoclax containing regimen and also to a lesser extent BTKi (ibrutinib/acalabrutini...